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Abstract: 
 
Antimicrobial peptides are key actors in organisms’ immune systems. They play an important role 
in phagocytosis, breaking bacteria membranes. They destroy the microbes, keeping them from repairing 
themselves, and therefore do not promote antimicrobial resistance.  
LL37 is a peptide produced by the human body. It is a short amino acid chain that is particularly 
active on the skin and mucous membranes. It has antimicrobial and fungal activity as well as wound 
healing properties, which makes it a very interesting active substance in wound treatment. However, its 
fragile and sensitive structure is a challenge to its use. Nowadays, encapsulation in a biocompatible 
polymer system is a promising technique in drug delivery, and presents a solution to LL37 administration 
and delivery. 
LL37 is a hydrophilic active substance, it will be trapped in PLGA (poly (lactic-co-glycolic acid)) by 
double emulsion and the microspheres will be shaped and stabilized by solvent evaporation. The capsules 
will be characterized by Dynamic Light Scattering (DLS) and Scanning Electron Microscopy. Their main 
features, drug loading, encapsulation efficiency and release profile, are determined using the Bradford 
assay. Since the peptide is expensive and delicate, it is important to optimize its encapsulation. For that 
reason, we will adapt the process to have the best drug loading as possible using water in oil in oil 
emulsions. 
For an external use, the capsules would be used over a few days, so having a fast release is very 
relevant.  The larger the specific surface area, the faster the diffusion. For that reason, we will also study 
the impact of porosity on the release profile. 
As a result, different types of capsules will be synthesized, with higher porosity and by two 
processes: aqueous double emulsion and oil double emulsion. Their characteristic features and impact on 
bacterial pathogens will be determined and compared in order to determine their optimal synthesis 
process and formulation in given conditions of use. 
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Introduction 
 
In 2013, the Center for Disease Control and Prevention published an alarming report about 
antibiotic resistance in the US. The overuse of antibiotics has been promoted bacteria and fungi 
resistances. Each year, this phenomenon causes more than 2 million illnesses which result in up to 23,000 
casualties [1].  
Antimicrobial peptides are an innovative technology that may present an effective alternative to 
treat infections in a way that does not lead to resistance versus antibiotics. Those peptides that are 
naturally synthesized by organisms can have other interesting features, such as wound healing properties.  
However, their fragility and sensitivity in atmospheric conditions makes it difficult to use them in ordinary 
drugs. Therefore, designing suitable delivery platforms for antimicrobial peptides is very important for the 
development of this biotechnology. Microencapsulation in a polymer is a way to conserve and use AMPs 
conveniently. 
LL37 is an antimicrobial peptide naturally synthesized by the human body. It showed antimicrobial 
and wound healing properties [5,7]. We will study its encapsulation in PLGA, a biodegradable and 
biocompatible polymer. 
  We synthesized LL37 PLGA capsules. We used the multiple emulsions with a solvent evaporation 
technique. This method was chosen because of the need to encapsulate a hydrophilic active substance 
like LL37 in a polymer that is lipophilic. 
The goal of the project is to design capsules that could be a suitable conservation and delivery 
platform for LL37 peptides. However, to have a technology adapted to routine use, diffusion needs to 
occur quickly. Therefore, changing the synthesis process to have a fast release from the spheres would be 
interesting. 
The specific aims of this project are: 
Aim 1: Synthesizing microcapsules with a satisfying LL37 loading 
 We will characterize the capsules produced by aqueous and oil double emulsions (respectively 
W/O/W and W/O/O) and ensure they fit the size specification of the project: between 0.1 and 100 μm [2]. 
Aim 2: Diffusion from the capsules in normal atmospheric conditions 
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 According to the literature, active principle release from PLGA capsules occurs while PLGA is 
degrading: release is complete when the polymer is entirely decomposed. 
 We will carry out a diffusion experiment over a few days in a media reproducing the physiological 
conditions (PBS), the amount of protein released will be quantify using a Bradford assay. Eventually, we 
should obtain a media cumulative protein concentration profile close to the literature results. With 
Scanning Electron Microscopy we could image the capsules after they start releasing their load to see the 
evolution of their structure. 
Aim 3: Conditions impact on diffusion 
 To measure the impact on external conditions on the capsules, the diffusion experiments will be 
repeated at: 
- Body temperature (36⁰C) in physiological conditions in PBS buffer, 
- Acidic pH (4.2), 
- Basic pH (10.2). 
The diffusion profiles will be obtained using the same method and assay. 
Aim 4: Designing porous capsules 
 To increase the release rate from the microcapsules, we will formulate porous PLGA capsules 
loaded with LL37. 
 In order to do that, we will slightly change our synthesis process. Increasing the inner aqueous 
phase volume versus the organic solvent one, more droplets are formed by emulsion. As a result, we 
hypothesize that there will be more pores filled with protein solution in the capsules. To trap the peptide 
inside the structure while it hardens during dichloromethane evaporation, the microspheres are dispersed 
in an organic chemical that is not soluble with any of the other phases involved in the process (liquid 
paraffin or silicone oil). At the end of the synthesis, the capsules are separated from the solvent by 
centrifugation and dried. 
They are characterized using SEM (structure), DLS (size) and Bradford assays (encapsulation efficiency). 
We will also carry out a diffusion study in ambient conditions to have a release profile to compare with 
the standard PLGA capsules. 
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Aim 5: Microspheres impact on bacteria  
 The impact of the spheres on bacterial growth will be investigated. The synthesized capsules will 
be tested against bacteria in a zone of inhibition study or put in contact with a standard solution of 
Escherichia Coli.  
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PART I - Background Information 
I – LL37: An Antimicrobial Peptide 
1) Overview  
The immune system protects the body by recognizing and eliminating foreign organisms. It triggers 
inflammation in reaction to an invader: that is effective and nonspecific but quite slow which actually 
allows microbes development. In the eighties, this paradox to the immune system efficiency was solved 
with the discovery and identification of antimicrobial peptides [7]. They are small, positively charged 
proteins made up of 27 to 50 amino acids. They were first discovered and isolated from insects but were 
quickly found to be a part of all multicellular organisms’ immune system [7]. Their high activity against 
bacteria, fungi, yeast and some viruses has been proven [3,6]: the minimum inhibitory and bactericide 
concentrations associated are very low [3]. They are natural and biological antibiotics. 
Antimicrobial peptides are released quickly after gene expression in response to pathogens detection. 
Their action is generally local since they are produced by epithelial or white blood cells’ ribosomes in 
almost all the organisms. However, they play a more important role in insects’ immune system where 
they are secreted by the hemolymph. 
More than 500 peptides have been identified so far, they are divided in three categories [7]. 
The Granulysins are exclusively present in the human immune system and are the only type of AMP also 
presenting an activity against some tumor cells. They are not produced by epithelial cells but brought 
onsite by the lymphocytes T contrary to the other types of peptides.   
The Defensins are rich in the cystein. This amino acid involves disulfide forming a complex structure 
consisting in helices and sheets. 
The cathelicidins are themselves linear AMPs characterized by their 
helix structures. The CAMP is the only gene coding for their 
synthesis in the human body [7] and it results in the AMP hCPA18 
often called LL37 since it consist in 37 amino acids (arginine and 
lysine are in blue, hydrophobic residues in green). 
This AMP is present in sweat and saliva. It is also stored and 
brought to the inflammation site by the phagocytes.  
    
Figure 1: LL37 3 dimensional structure [11] 
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Those peptides are cationic, which makes them soluble in water. Nonetheless, they also have a 
hydrophobic part which makes them amphiphile.  
2) Action process 
The structure and properties of the cathelicidins and particularly of LL37 are key in the mechanisms 
of those peptides against bacteria. 
Indeed, the microbes have membranes that are rich in anionic phospholipids to which the AMPs’ 
cationic side is attracted. Moreover, those membranes generally 
have a hydrocarbon core located on average 300 nm across them 
that the helical structures can easily reach with their length and 
amphiphilicity. For example, LL37 is around 555 nm long 
considering each amino acid to be 15 nm on average [6].  
Penetrating the membrane, the peptides disrupt it by 
forming pores or by a detergent effect [5,7]. In the case of LL37, 
the disruption follows a toroidal pore formation model.  They 
accumulate on the surface of bacteria membrane through 
electrostatic interactions. The helix structure of LL37 enables it 
to insert itself in the bilayer with lipophilic interactions and 
makes it bend until it exposes the core. 
As a result, the cell is permeated which interfere with its 
biological processes: the peptides can target the core’s anionic 
molecules or receptors preventing the synthesis of essential 
proteins through RNA or enzyme modification, intra and extracellular ionic concentrations are balanced 
causing an energy drain. Those phenomena end up causing the bacteria lysis. 
Peptides do not interact only with bacteria. Some receptors on immune cells also respond to their 
presence which makes them essential. LL37 stimulates some small proteins that manage macrophages 
called chemokines. The latter can bring neutrophils and monocytes on site, definitely stopping infection.  
AMPs presence triggers: 
- angiogenesis [12;7] which keeps the cells in the inflammation area oxygenated, 
- keratinocytes migration [7] to the wound enabling its closure. 
 
 
Figure 2: Toroidal model of antimicrobial peptide induced 
killing [5] 
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Antimicrobial peptides are an essential piece of the immune system. Their action is required for a 
complete action against infection. 
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Figure 3:Antimicrobial Peptides action process as a part of the human immune system 
17 
  
3) Advantages of AMPs 
 Because of AMPs’ various action processes, the development of bacteria resistance is very 
unlikely. So far, the only resistance mechanism brought to light was a slight decrease in the bacteria 
membrane charge which comes with a high energy cost. The non-resistance has been confirmed by 
research and long term use [8]. Nisin is an AMP that has been used in industry as a food preservative since 
the 1960s. Its use has indeed not brought any resistance from its targets or weakened the consumers’ 
immunity [12]. It is important to notice that the AMPs are effective against both gram positive and gram 
negative bacteria [4;6] in spite of their different membrane structures. 
 
 Nonetheless, the difference between mammalian and bacterial cells’ membranes is significant in 
the AMPs action mechanism. Their compositions and properties are different. Bacteria membranes are 
essentially made up of anionic phospholipids that can be easily permeated while the cells in our organism 
consist of neutral phospholipids stabilized by cholesterol [9].  For that reason, AMPs affect almost 
exclusively foreign bodies unless the concentrations are very high. 
 Not only are AMPs non-toxic to the organism, but they are also biocompatible since they are 
naturally present in the human immune system. However, because they are produced by the organism, 
their complex structure is hard to reproduce: the chemical synthesis now used is very expensive and the 
productivity is low [3]. Adding to that, antimicrobial peptides are hard to store, they degrade quickly in 
normal conditions. Thus, antibiotics are currently the best treatment option against microbes. More 
research is needed on formulation and process scaling up before AMPs will be commercially viable. 
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II- PLGA and Encapsulation for Drug Delivery 
1) A revolutionary biocompatible polymer, PLGA: 
 The polymerization of lactide and glycolide cycles result in the synthesis of PLGA or Poly Lactic-
co-Glycolic Acid: 
    
R
O
O
O
H
O
CH
3
O
n
 
m
 
 
Figure 4:Chemical structure of PLGA 
 The nature itself of the polymerization process has a strong impact on the product including its 
length and composition: proportion between the lactide (n) and glycolide (m) blocks. That leads to several 
types of PLGA with different molar mass and properties. The molar mass increases when the number of 
lactide blocks (higher molar mass than glycolide group) in the polymeric chain or proportion n: m 
increases. As a consequence, the glass transition temperature of PLGA will increase too, they are typically 
between 34 and 40°C for all the types of PLGA [15]. 
 This polymer is soluble in almost all the organic polar solvents: Dichloromethane (Polarity Index 
3.1), Acetone (5.1), Chloroform (4.1), Acetonitrile (5.8)… Indeed, because of the presence of the methyl 
function in the lactide block, PLGA is hydrophobic [15]. However, it interacts with water by its ester 
functions causing the hydrolysis of the polymer according to the following reaction:  
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Figure 5: Hydrolysis of PLGA 
 
 The degradation is faster when the PLGA is among the most hydrophilic of its copolymer so when 
there is less lactide blocks containing hydrophobic methyl groups. Indeed, hydration of the 
macromolecule is less important leading to a slower process. 
On the other hand, the linearity of the glycolide function brings crystallinity to the polymer [14;15] while 
the presence of the methyl group in polylactide keeps the molecules to order themselves with respect to 
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one another. Thus, the higher the ratio n: m, the less crystalline the structure and the faster the 
degradation. 
Because of that paradox, the fastest copolymer to degrade under hydrolysis is the Poly Lactic-co-Glycolic 
Acid n: m containing as much polylactide as polyglycolide, the PLGA 50:50. 
 
2) Biodegradability & biocompatibility: 
 PLGA copolymers are quickly degraded in contact with water through the hydrolysis reaction 
previously presented. The following graph shows the degradation in specific conditions of microparticles 
having the same size and geometry and made up of different copolymers. 
The hydrolysis process is very fast and takes place over a month approximately. Nonetheless, the 
literature points out that the degradation rate also depends on other factors [13]: pH, temperature, 
composition of the media, size and porosity of the polymer particles (faster diffusion when the surface to 
volume ratio increases).  
  
 The hydrolysis is progressive and results in a decrease of the molecular weight of the polymer 
macromolecules and in the release of two chemicals: lactic and glycolic acids. Their concentration 
increases while the polymer is degrading involves a slight pH decrease.  
This phenomenon combined to the injection and presence of PLGA detected as a foreign body by the 
organism triggers a local inflammation reaction [16]. However, the duration of the inflammation is short 
and the pH decrease not significant enough to leave the physiological range [17].  
 
 
Figure 6: Decrease in molecular weight of various microspheres as 
a function of time [14] 
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 Moreover, the glycolic acid is cleared by the metabolism through kidney elimination whether 
unchanged or after decomposition in carbon dioxide and water like lactic acid. For that reason, those 
compounds do not actually have a harmful impact on the human body[15]: they are easily detected and 
completely cleared by the immune system. Another biopharmaceutical interesting fact about this polymer 
is that the lactic acid is the conjugate acid of lactate which promotes angiogenesis involving tissues 
reconstitution and wound healing [21]. 
 For that reason, PLGA is a biodegradable and biocompatible material. That was confirmed after 
its use on patients who did not suffer from any toxicity effect. Thus, the FDA approved the use of PLGA in 
pharmaceutical applications [15]. 
3) An interesting material in drug delivery platform design 
 Drug delivery is one of the fields to benefit from the development of biomaterials. The progress 
in platform design at micro and nano scales induced the development of new and innovative drug delivery 
system. The tunability and size of the platforms revolutionized patients’ treatments. Those methods 
enable an efficient and targeted delivery of the drug which permits a more accurate and better drug 
concentration adjustment, limiting side effects and toxicity. Indeed, thanks to the last outcomes of that 
technology, the medicine reaches the concerned tissues without affecting the healthy cells and without 
even being detected by the immune system. This is particularly interesting when there is a need to deliver 
a toxic medicine such as cancer drugs. This technology is currently used in all the state of the art 
treatments to cure that disease. 
 The biocompatibility and biodegradability of Poly(lactic-co-glycolic acid)  makes it particularly 
interesting for medical applications. Moreover, it can easily be shaped and functionalized, we can process 
it to a suitable platform by different methods depending on the medical use for that material: implants 
design, treatment or imagery agent delivery [27; 15]. 
 In the case of implants, PLGA can be molded or submitted to a more complex process depending 
on their composition and if they also provide a sustained delivery of a therapeutic agent.  
Extrusion and spray drying are used when smaller PLGA particles need to be formed [15]. Those methods 
are more difficult to carry out and require more material than shaping the biopolymer after dissolution in 
an organic solvent miscible with PLGA.  
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 Dissolved PLGA can be used to synthesize different types of products: PLGA particles, liposomes 
and capsules. The type of platform and process depends on the drug properties, whether it is lipophilic or 
hydrophilic particularly, and on the characteristics wanted. 
Dissolution of PLGA and emulsion is a possible method to synthesize particles. They can be used to deliver 
an active substance using functionalization to graft it on its surface. This process can be used with 
molecules that are not affected by their environment conditions.  
 For more fragile substances such as peptides, encapsulation is a better option. There are different 
possible types of capsules: 
- Liposomes [18; 19], bilayer of polymer around a core containing the hydrophilic therapeutic agent in 
a given concentration. This structure can be multi lamellar which makes it interesting for a multidrug or 
progressive release (different concentrations). Lipophilic drugs can be contained in the vesicles 
membranes, 
- Bulk polymer particles in the case of hydrophobic drugs that are soluble with the organic phase, they 
are obtained after simple oil in water emulsion and drying, 
- Polymer matrices with pores filled with hydrophilic drug. The polymer being soluble in an organic 
solvent a double emulsion method followed by an evaporation of the solvent is required to trap the drug 
inside the polymer shell. That is the synthesis method used for LL37 encapsulation. Two multiple 
emulsions can be considered: water in oil in water or water in oil in oil [34].  
Dealing with an emulsion method requires the use of surfactants for stabilization [43]. 
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Figure 7: Encapsulation by water in oil in water double emulsion 
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III –Peptides Encapsulation 
1) Peptides Encapsulation Methods 
 Most of proteins are hydrophilic or amphiphilic. That property reduces the encapsulation 
methods of peptides to three main processes. 
 Loading the proteins in liposomes is generally done by thin film hydration [18; 19]. It consists in 
forming lipid bilayer by solvent evaporation on a surface that is then hydrated with a peptide solution 
which involves membrane expansion. The bilayers get loose and form spheres where the active substance 
is trapped when energy is brought to the system by agitation or sonication. The vesicles can be processed 
further to reach some specifications: size, structure (multi lamellar or simple unilamellar vesicle), 
functionalization (targeting agent, stealth elements)… The protein can be localized in the membrane or 
inside the liposomes depending on the importance of its lipophilic aspect versus its hydrophilic side. 
 
 
Figure 8: Liposomes formation [18] 
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 Multiple emulsions are very common in a lot of industrial fields (pharmaceutics, food, cosmetics, 
construction…) and it is also another way to incorporate proteins in a lipid or polymer matrix. The first 
step consists in dispersing the peptide aqueous solution into an organic phase. The synthesis can follow 
two pathways from there: 
- The organic phase can be melted polymer or lipid only [26]. The first W/O emulsion is then 
homogenized in water. This enables the formation of peptide loaded spheres and their 
solidification over time thanks to the high water heat capacity that cools the system down, 
- A solvent where the polymer or lipid is dissolved can constitute the organic phase. To form the 
capsules, the primary suspension is dispersed in an outer organic or aqueous liquid not miscible 
with the first oil phase. The solvent can then diffuse and evaporate from the whole system 
involving the matrix hardening. Nonetheless even if the second phase can consist in an organic 
chemical or water, the use of a compound that is not soluble with either of the inner emulsion 
phases is preferable to avoid the migration of the therapeutic agent out of the capsules or at their 
surface during solvent evaporation as explained by Viswanathan et Al. [23]. 
That latter method must succeeded by Separation, purification, drying and sometimes sieving steps 
before obtaining a suitable product that meets the specifications. 
2) Antimicrobial Peptides encapsulation in the food industry 
 Keeping food from bacteria contamination is an important issue in our industrialized consumption 
society.  The strong will to reduce the use of chemicals in the food industry drives the research and 
development of biological and natural agents to replace them. Antimicrobial peptides are a serious 
alternative.  
 Bacteriocins and Nisin are two peptides that have been used as preservatives so far. However, 
their direct use, free in solution presents some problems. Peptides present very fragile structures, they 
degrade quickly because of the outer conditions or their interactions with other ingredients. According to 
Da Silva et Al. [22], incorporating nisin in liposomes is preserving its activity. The structure protects the 
peptide that is released progressively which actually increases their impact over time: they are more 
effective as preservative agents. Their stability is increased in liposomes where the phospholipid 
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membrane immobilizes the proteins because of their amphiphilic feature. The composition of the bilayer 
can be changed depending on the release profile desired. The efficiency is improved with this structure 
compared to the free peptide and showed an increase in the preservation time of some products through 
the inhibition of bacterial growth. For a similar application, Balcao et Al. [20] reached the same conclusions 
for bovine lactoferrin when encapsulated in a lipid matrix by water in oil in water emulsion. 
 Indolicidin is another bovine AMP. It presents very promising antifungal properties but 
unfortunately no selective toxicity. Its toxicity must be control first before to enable its use in any food or 
pharmaceutical products. Ahmad, Perkins et Al. [19] could use the liposome technology to trap this 
substance. Not only did it maintain its antimicrobial properties but also significantly reduced its toxicity 
towards healthy cells through a sustained release determined by the formulation and synthesis. 
3) LL37 encapsulation for biopharmaceutical application 
 LL37 is an AMP that is particularly interesting for its wound healing and antimicrobial properties, 
it could thus have biopharmaceutical applications. Unfortunately, its structure is very sensitive to external 
conditions which can reduce its activity. Encapsulation protects the compound and guarantees its activity 
during a sustained delivery. 
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 Chereddy et Al. [21] prepared wound healing nanoparticles by combining lactate and LL37 
therapeutic effects. In order to do so, the peptide was trapped into PLGA nanoparticles by water in oil in 
water emulsion followed by solvent evaporation, dichloromethane in this case. Indeed, PLGA degradation 
partly results in lactic acid which dissociates in lactate that is thus released with LL37. LL37 nanoparticles 
showed a higher wound healing rate for a same injury than PLGA NPs or LL37 or lactate on their own. 
  
 MTT assays showed no sign of toxicity from the nanoparticles towards healthy cells. Nevertheless, 
toxicity of nanoparticles on the human organism is a burning topic since this issue is critical for Public 
Health. Indeed, their size and the different materials they are made up of can make them hard to be 
metabolized in which case they accumulate in some organs. The potential risk they could present to the 
organism has not been fully discarded yet by the different Health Agencies (FDA, European Medicine 
Agency…) for all types of applications.  
That is why this study consists in synthesizing PLGA micro particles loaded with LL37. Their antimicrobial 
 
Figure 9:Dose–response curve of different controls and PLGA-LL37 NP for wound healing activity: (a) LL37, (b) D,L lactic acid, (c) PLGA-NP 
and (d) PLGA-LL37 NP (mean ± SD; n=10) [21] 
28 
  
effect will be tested and the release of the peptide in different external conditions will be investigated in 
function of different formulations and processes. The diffusion examination of LL37 from the 
nanoparticles at 25°C and pH 7.4 obtained by Chereddy et Al. [21] in their wound healing NPs study 
provides an idea of the profile to expect.  
The size being a key factor in diffusion [38], a shorter release time is to be expected for microcapsules.  
  
 
Figure 10: In vitro release of LL37 (plotted as a function of % 
cumulative release vs time) from PLGA nanoparticles loaded  LL37 
(Mean ± st dev; n= 3) 
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PART II- Encapsulation Methodology 
 
I - Water in Oil in Water double emulsion with solvent 
evaporation 
1) Method 
 LL37 is a hydrophilic peptide: before to trap the protein in the PLGA containing phase, dissolving 
it in water first is required. LL37 comes in a lyophilized powder form. It is dissolved in ultrapure water with 
PBS buffered at pH 7.4. The aqueous media is autoclaved to be sterilized and filtered before dissolving the 
protein. The solutions were prepared depending on the mass of peptide we wanted to trap inside a given 
batch of capsules. According to the Minimum Inhibitory Concentration studies carried out on LL37 (see 
part IV), the concentration required for LL37 to eradicate bacteria of Mac Farland standard 0.5 is 0.33 
μmol/L or 1.5 μg/mL (MW(LL37)=4493.33g/mol). That is why it has been decided to encapsulate 153 μg 
in each batch of capsules: several samples from each of them can thus be used. 
LL37 is then encapsulated in PLGA microspheres. 
 The two ways to shape a polymer are by melting it or dissolving it into organic solvent. The most 
convenient method to form microspheres is by dissolution and dispersion into a liquid in which PLGA is 
not miscible. For that reason, PLGA is dissolved in an organic solvent and then dispersed into another 
liquid it is not miscible with to form spheres that harden while the solvent is evaporating. 
Since we want to encapsulate LL37 in the polymer matrix, the first step is to include the peptide solution 
to the organic one. The two are not miscible: a dispersion of the aqueous solution into the polymer 
mixture is performed to have a high contact surface between the two phases. This first emulsion must 
remain stable to form loaded microspheres. For that reason the surfactant Span 60 is used to stabilize this 
primary water in oil emulsion and keep a suspension structure. 
 The suspension of aqueous solution in organic solvent containing PLGA is then homogenized with 
a large volume of water. The organic solvent and PLGA being not soluble with water, the microspheres 
consisting in the primary emulsion are formed. Thanks to the use of the surfactant polyvinyl alcohol (PVA) 
[43], those spheres do not coalesce. The solvent evaporates overnight and the polymer hardens, trapping 
droplets of peptide solutions before it can migrate to the continuous phase. 
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2) Reagents and Protocol 
 In order to have 153.83 ug of LL37 in 0.2 mL of peptide solution, 769.23 μg /mL LL37 solutions 
were prepared from 1 g lyophilized LL37 powder purchased from Anaspec. The powder was dissolved in 
aqueous phosphate buffered (pH 7.4) saline made from Sigma Aldrich PBS saline buffer, that was sterilized 
with AN autoclave and filtered with a 0.22 nm sterile filter from Olympus.  
 The organic phase was prepared with 3.2 mL of HPLC grade dichloromethane in which 0.2g of 
PLGA 50:50 (MW 30,000-60,000 g/mol) (12.5% w/v) and 0.016g of Span 60 (5% mass with respect to the 
volume) were dissolved. All the chemicals are from Sigma Aldrich. 
 0.2 mL of the LL37 solution was dispersed into the PLGA phase to form a stable primary water in 
oil emulsion with an Ultra Turrax T25 homogenizer from IKA used for three minutes at 6,000 rpm. 
 The suspension is then emulsified dropwise with 40 mL of phosphate buffered saline (pH 7.4) 
containing 5% w/v of Polyvinyl Alcohol. The mixture is homogenized for 3 minutes at 4,000 rpm, a lower 
speed than for the first step in order to keep the shear from breaking the first emulsion. 
 The powerful high shear homogenization combined with the use of surfactant give a stable 
suspension that hardens overnight under 500 rpm magnetic stirring resulting in PLGA microspheres 
containing peptide droplets after complete solvent evaporation. 
3) Product Purification 
 The spheres are collected by centrifugation.  
They are rinsed with PBS aqueous buffer and centrifuged three times to remove any remaining PVA.  
 Finally, they are lyophilized at -40°C in a container that maximizes the exchange surfaces involved 
in the process.  
Microspheres with pores filled with solid LL37 are obtained. We store them in containers made watertight 
thanks to the use of parafilm at -4°C.  
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II - Water in Oil in Oil double emulsion with solvent extraction/ 
evaporation 
1) Method 
 Multiple emulsion with solvent evaporation is a good method to encapsulate substances into 
polymers. However, the encapsulation only occurs in a satisfying way if the different emulsions remain 
stable during the evaporation of the solvent that takes up to 24 hours depending on the volatility of the 
solvent and on the volumes and conditions (pressure, temperature) that are used [28]. Indeed, the 
polymer phase viscosity increases while the solvent is evaporating. For that reason, if the emulsions are 
not stable long enough, we can observe two phenomena: 
- The polymer organic droplets gather to form a unique organic phase or aggregates. The solutions 
to that problem are to lower the pressure and increase the temperature (while keeping it lower 
than the transition temperature of PLGA, which is around 42°C for PLGA 50:50 depending on the 
intrinsic polymer characteristics) or to use an adapted agitation than can provide enough energy 
to the system to maintain the suspension. 
- The instability of the emulsions can cause the inner aqueous phase migration to the bulk one, 
leaving empty polymer spheres. This phenomenon is even more important when the bulk and 
inner phases are miscible. 
 To increase the amount of protein solution trapped in the polymer, we can use a bulk phase that 
is not miscible with water to keep the peptide trapped inside the polymer solution. However, to be able 
to use the emulsion method, the bulk phase also needs to be immiscible with the polymer and non-volatile 
so the solvent evaporation can be performed. 
 Paraffin is a mineral oil, mixture of different hydrocarbons. It is not miscible with water and with 
PLGA. It is very stable and has a very high boiling point: it is not volatile. Nonetheless, paraffin is a very 
viscous fluid. Indeed, the one used in the experiment (purchased from Sigma Aldrich and meeting the 
European Pharmacopoeia specifications) has a dynamic viscosity between 110-230 mPa.s in normal 
conditions of temperature and pressure. 
Paraffin properties are crucial in the emulsion and solvent evaporation process: 
- The second emulsion in the bulk paraffin phase cannot be done with a high shear homogenizer in 
such a viscous fluid. The viscosity of the bulk phase needs to be decreased during that step. This 
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can be done mixing paraffin with another non miscible organic solvent. That solvent needs to be 
immiscible with water and PLGA but miscible with paraffin. It is also required that it does not stay 
into the system: a volatile chemical is preferable. Hexane has a low boiling point (69°C), is a non-
solvent of PLGA and soluble in paraffin but not in water.  
- More energy needs to be provided by the stirrer to the system during solvent evaporation to 
maintain the suspension. Indeed, the more viscous the medium is the more energy is dissipated 
in the fluid. Agitations provided by rotation stirring (rotary evaporator) and magnetic stirring does 
not provide enough energy to that system, the suspension is not maintained during solvent 
evaporation which causes aggregation, whether it is by forming ribbons and aggregates or a film 
on the container walls. Mechanical stirring is required. 
- Dichloromethane is very soluble in paraffin, its extraction from the polymer phase is a fast 
phenomenon in those conditions. It is extracted first from the surface of the droplets keeping the 
active substance trapped and avoiding its migration and solidification at the polymer/paraffin 
interface. While DCM diffuses to the bulk paraffin phase, those soft spheres delimited by a hard 
layer are still deformed by the agitation shear forces giving ribbons and lumps shapes after 
solidification. To keep the spherical shape, it is necessary to have a slower increase in viscosity. 
That is done by combining dichloromethane with another solvent of PLGA that is not soluble with 
paraffin: acetonitrile. According to Viswanathan et al [23], the mixed solvent system must contain 
as much AN as DCM or 70% AN and 30% DCM or 30% AN and 70% DCM to avoid any aggregation 
phenomenon. 
Microcapsules aggregation in paraffin is also prevented by the use of a surfactant in the dispersing 
phase. While polyvinyl alcohol was used to decrease the spheres surface tension in the aqueous emulsion 
and solvent evaporation process described in the previous part, it is not soluble in paraffin. SPAN 80 is a 
viscous surfactant (kinetic viscosity: between 1000 and 2000 mPa.s at 20°C) which is dissolved into 
paraffin in this process [25;32]. 
 
2) Reagents and Protocol 
 The water in oil in oil solvent evaporation is performed dissolving 0.2g on PLGA 50:50 and 0.016g 
of SPAN 60 in 1.6 mL of HPLC grade Dichloromethane. Once dissolved 1.6 mL of Acetonitrile is added. AN 
is not soluble with SPAN 60, a progressive addition (in three times) under agitation is required. As 
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mentioned in this protocol, a 50:50 ratio is used for the mixed solvent system. Indeed, the trials with the 
other two ratios also advised by Viswanathan et al [23] resulted in an aggregation of the polymer into 
lumps or ribbons. 
 The latter organic phase is homogenized for three minutes with 0.2 mL of 769.23 μg /mL LL37 
solution with the Ultra Turrax at 25,000 rpm. 
 The water in oil emulsion is then homogenized a second time for three minutes at 22,000 rpm in 
40mL of paraffin previously mixed with 4 mL of SPAN 80 and 9 mL of hexane.  
 The double emulsion is finally stirred with an ARROW 1750 mechanical stirrer at 600 rpm (setting 
3) for 24 hours (overnight stirring). Because of the system viscosity, the agitation module used with the 
overhead stirrer is a propeller. Given the evaporation of solvents, the synthesis must be carried out under 
a fume hood. 
3) Product Purification 
 After 24h, 10 mL of hexane are added to the system to decrease its viscosity and finalize the 
capsules hardening. After mixing, the suspension is centrifuged. The spheres are rinsed with hexane and 
centrifuged three times. They are finally freeze dried. 
II – Porosity Increase 
1) Method 
 At the end of the synthesis, the resulting capsules consist in peptide solution droplets dispersed 
in a solid PLGA matrix. The water from it is sublimated during freeze drying leaving a pores filled with solid 
LL37. Studying the impact of porosity on the substance release was interesting. In order to test that 
feature, microspheres with higher porosity were prepared [33]. To increase the volume of pores with 
respect to the mass of PLGA within the spheres, the volume of the peptide solution used was doubled to 
0.4mL while the same total mass was encapsulated per batch.   
2) Reagents and Protocol 
 153 μg of LL37 were encapsulated in the processes previously presented (0.2 mL of 769.23 μg 
LL37/mL) for 0.2 g of PLGA used. In order to encapsulate the same total mass of peptide per batch of 
spheres doubling the volume of the active substance phase, the aliquots prepared to synthesize regular 
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capsules (part I and II) were diluted by two resulting in solution at a concentration of 384.62 μg of LL37 
per mL. 
 At the exception of the volume and concentration of the inner aqueous phase (0.4mL at 384.62 
μg LL37/mL), the exact same protocol as for the water in oil in water solvent extraction evaporation 
process presented in the previous part was followed. 
3) Product Purification 
 After synthesis, the microspheres are treated following the same protocol as in part II: cleaned 
three times with hexane and freeze dried. A white free flowing powder is obtained. 
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PART III- Results and Discussion 
Characterization 
I – Size 
 The risks involved by the use of nanoparticles have not been fully assessed yet. For that reason, it 
is important to obtain microspheres from the different processes used (strirring speeds were 
experimentally optimized for that). According to the IUPAC [2], micro particles are defined as objects 
which characteristic length is between 0.1 and 100 μm. When the particles are smaller than 10μm, they 
can be sized with Dynamic Light Scattering (Zetasizer). The particles produced in this study being larger 
than 10μm, the size distributions were plotted after analyzing light microscopy pictures with the software 
Image J. 
1) Method for sizing microspheres by microscopy 
 Two batches of capsules were synthesized per synthesis method, they are labelled: 
 
Table 1: Numbers associated with the batches processed 
 Samples of each batch are suspended in a 0.1mg/L PVA solution to avoid capsules aggregation. The 
suspensions are prepared for light microscopy. Several pictures (between 5 and 10 depending on the 
concentration of the sample) of different areas of the samples were taken. The method is illustrated with 
an image from one the first batch of capsules realized by the regular water in oil in oil method.  
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Figure 11: Image from a sample of batch 4 (x10) 
Images are treated one by one. First, the scale is set depending on the magnification used. The scale can 
be displayed on each image. 
 
Figure 12: Image from a sample of batch 4 (x10) with scale bar 
The second step to prepare the picture for size analysis is to convert it to black and white (8bit).  
 
Figure 13: Image from a sample of batch 4 (x10) (8bit) 
 The software needs detect the particles to measure them by making the distinction between them 
and the background. That is done by having a clear color distinction between the background and the 
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particles making the picture binary. However, if there are some light discrepancies in a same picture, the 
software will never be able to make the clear distinction between some parts of the background and the 
capsules. In that case, dividing a picture in different areas having the same light intensity and analyzing 
them separately is required. 
 
Figure 14:Binary image from a sample of batch 4 (x10) (8bit) 
 
 The spheres do not have a perfectly smooth surface which can cause the presence of white holes 
in the capsules detected by the software (in black). The software integrates and gives the surfaces of the 
particles it detects. For that reason, the presence of those holes would contribute to a wrong reduction 
of the diameters. Filling the holes using Binary>Fill holes is required to obtain a satisfying image to perform 
size analysis. 
 
Figure 15: Full binary image from a sample of batch 4 (x10) (8bit) 
 
 The detection of the particles must be verified by using the function “Threshold”. The red spots 
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are areas that are taken into account as particles by the software. If the selection does not correspond to 
the reality, the threshold must be adjusted. 
 
Figure 16: Image J threshold function applied to an image from a sample of batch 4 (x10) (8bit) 
 
If the right particles are detected, the picture can finally be analyzed. Image J provides a table with the 
areas of all the particles detected under the following format: 
 
Table 2: Table provided by ImageJ sampled to five first particles measured by the software from a picture of a batch 4 
sample(x10) (8bit) 
For each batch of capsules, the data obtained for different samples and pictures are collected in an excel 
file where the results are sorted out. The diameters of the particles are calculated from the areas provided 
by ImageJ assuming the capsules are perfectly spherical. The average and standard deviation are 
determined. Thanks to those values, the normal law can be applied to obtain the frequency of each 
diameter. The size distribution gaussian curve for each batch corresponds to the plot of frequencies versus 
diameters. For Batch 4 was obtained: 
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Table 3: Batch 4 Size analysis 
 
 
Table 4: Size Distribution obtained for Batch 4 after microscopy size analysis with Image J 
Small microspheres were not taken into account for this batch which is probably due to image resolution 
issues, the Gaussian curve should probably be centered on a slightly smaller diameter in ideal conditions. 
 
2) Results and Discussion 
 The microscopy sizing method was applied to all the batches of capsules synthesized. The sizes 
differed from one process to another. 
a) Water (0.2mL) in Oil in Water double emulsion solvent evaporation process: 
Capsules from batch 2 and 3 had an average diameter of 47.5 μm. 
average diameter (μm) standard deviation
82.20176837 78.23862466
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Figure 17: Batch 2 Size Distribution 
 
Table 5: Batch 2 Size Distribution Analysis 
  
Figure 18: Batch 3 Size Distribution 
 
Table 6: Batch 3  Size Distribution Analysis 
average diameter (um) standard  deviation # of particles
49.86 23.30 59
average diameter (um) standard  deviation # of particles
45.04 19.76 90
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The water in oil in water emulsion and solvent evaporation process is reproducible. However, the number 
of particles analyzed varies in the two studies which has a significant impact on the standard deviation. 
b) Water (0.2mL) in Oil in Oil double emulsion solvent extraction/evaporation process: 
The microspheres produced by that synthesis method (batch 4 and 5) have an average diameter of 89μm.  
 
Figure 19: Batch 4 Size Distribution 
 
Table 7: Batch 4 Size Distribution Analysis 
  
Figure 20: Batch 5 Size Distribution 
average diameter (μm) standard deviation # of particles
88.12 78.83 173.00
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Table 8:Batch 5 Size Distribution Analysis 
The number of particles analyzed for batch 4 is much higher than for batch 5 resulting in a much higher 
standard deviation. The two averages around which their particle sizes are distributed are nonetheless 
coherent. 
c) Water (0.4mL) in Oil in Oil double emulsion solvent extraction/evaporation process: 
From this process, capsules with an average diameter of 97 μm. 
 
Figure 21: Batch 6 Size Distribution 
 
Table 9: Batch 6 Size Distribution Analysis 
average diameter (um) standard  deviation # of particles
90.01 37.62 60.00
average diameter (um) standard  deviation # of particles
102.33 35.37 53.00
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Figure 22: Batch 7 Size Distribution 
 
 
Table 10: Batch 7 Size Distribution Analysis 
d) Discussion 
 For the w/o/w synthesis, using the same homogenization and stirring speeds as in the water in oil 
in oil process leaded to nanospheres. The settings were optimized to obtain the speeds used in the 
protocol: the best ones to obtain microspheres while keeping a satifying standard deviation.  
Microspheres obtained from the water in oil in water process are smaller than those produced from the 
water in oil in oil processes (in accordance with [34]). This is explained by the difference of viscosity 
between the two continuous phase: the paraffin used has a viscosity between 100 to 230 mPa-s according 
to the provider sigma. Thus, during the second homogenization and the solvent extraction/evaporation 
process, a greater proportion of the energy brought by the agitation is dissipated in the oil. The energy 
left to decrease the surface tension of the emulsion is lower leading to bigger particles having bigger sizes. 
 As for the two water in oil in oil processes, the synthesis involving an inner peptide solution 
volume of 0.2 mL leads to smaller microspheres on average that the one produced with a twice as large 
inner volume. However, given the value of their standard deviation we can consider that they produce 
particles having comparable diameters, around 93μm (average for batches 4 to 7). Decreasing the size of 
those particles maintaining favorable experimental conditions is very hard because of the nature of the 
average diameter (um) standard  deviation # of particles
92.48 40.96 84.00
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continuous phase. Moreover, it is required to use an agitation speed at which no air bubble is formed into 
the system. Indeed, the surfactant would then also contribute to stabilize those bubbles which would 
decrease its availability for the emulsion stabilization. Polymer aggregates would form. 
 An alternative  obtain comparable microspheres sizes for all the processes was to increase the 
size of the ones obtained with the w/o/w synthesis by decreasing the homogenization and stirring speeds. 
As a result, bigger microcapsules are obtained but the size distributions become larger. For that reason, 
adding a sieving step at the end of the processes would be the best way to increase control on the spheres 
sizes. 
II - Scanning Electron Microscopy Observations 
 To observe the 3D structure of the microspheres produced, scanning electron microscopy is used. 
That technique gives further information about the surface roughness, the shape of the particles but also 
their size. The structure of capsules post diffusion study will also be imaged to see how important the role 
of matrix erosion is in for drug release.  
1) Sample Preparation method 
 In order to obtain a good images from the Scanning Electron Microscopy, the samples must be 
treated before imagery. The treatment depends entirely on the type of material observed. The only 
requirement common to any sample observed is to be completely dry since SEM takes place under 
vacuum. 
 The capsules are made up of PLGA which is a polymer. It is not a conductive material and it tends 
to trap the electrons, which increases its charge leading to the appearance of white blurred spots during 
imagery. For those reasons, the samples must be sputtered with gold before imaging. The thickness of the 
layer is adapted to the particles sizes: the smaller they are, the thinner the gold layer. However low voltage 
(5keV) are used for imagery because of the nature of the material that could melt at higher voltage. 
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2) SEM Pictures 
The capsules synthesized were imaged by Scanning Electron Microscopy: 
- W/O/W: 
 
 Figure 23: SEM picture of W/O/W capsules loaded with 0.2 mL LL37 solution 
 
- W/O/O with a 0.2 mL LL37 solution: 
 
 
 Figure 24: SEM picture of W/O/O capsules loaded with 0.2 mL LL37 solution 
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- W/O/O with a 0.4 mL LL37 solution: 
 
 
 Figure 25:SEM picture of W/O/O capsules loaded with 0.4 mL LL37 solution 
  
 The capsules have a smoother surface when they are synthesized by the oil based process. The 
W/O/W spheres presents a porous and more irregular surface. This is due to different solvents used in 
the two processes. In the case of the oil based process, DCM is quickly extracted by paraffin while it slowly 
evaporates during the W/O/W synthesis, allowing pores formation. 
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III- Encapsulation Efficiency 
 After encapsulation, determining the amount of drug really trapped in spheres compared to the 
amount involved in the process is essential to characterize the product: 𝐸. 𝐸.=
𝑚𝑎𝑠𝑠 𝑟𝑒𝑎𝑙𝑙𝑦 𝑡𝑟𝑎𝑝𝑝𝑒𝑑
𝑚𝑎𝑠𝑠 𝑎𝑖𝑚𝑒𝑑
. Thus, 
it is necessary to define a procedure to quantify LL37 peptides. LL37 is a 37 amino acids long chain which 
sequence contains Arginine (5 times), Histidine (1 time) and Lysine (6 times) amino acids. 
Coomassie Blue is a stain that turns blue when it binds strongly with arginine but also through its weak 
interactions with His and Lys. This chemical is used to quantify compatible proteins by performing an 
experimental technique called Bradford assay. When equal volumes are considered, there will be more 
interactions as the concentration of protein in solution increases making the mixture bluer:  
 
Figure 26: Bradford assay performed on BSA, concentrations increasing from bottom to top 
1) Bradford Assay 
 LL37 amino acids bind with coomassie blue: it can be quantified using a Braford assay. Coomassie 
Blue was purchased from Thermo Scientific and the protocol [36] they provided for their product was 
followed.  
 It is important to check that there is no substance that can possibly interfere with coomassie blue 
in the solution to analyze: the different compounds and their limit in concentrations for the assay to be 
reliable are also given in the provider Manual. Spheres prepared only with PBS buffer did not interact with 
the stain: no interference is expected from the capsules made following the different processes carried 
out in this study. Coomassie brilliant blue binds strongly to glass, the use of disposable plastic cuvettes is 
required to obtain reliable results from the assay. 
 Concentrations from 1 to 25 μg/mL and 100 to 1500 μg/mL can detected by the chemical. The 
volumes of stain and solution used in the procedure depends on the range of the measured 
concentrations range. In the case of LL37, the encapsulation were started with 153µg of peptide. Total 
48 
  
encapsulation is never performed and only samples of the batches are analyzed: the concentrations 
measured are in the 1 to 25µg/mL range. 
 In that range, the provider protocol for performing the assay in micro plates was to use 150µL of 
peptide solution with 150µL of stain in each well. For an optimal reading and in order to obtain a 
homogeneous mixture, it was noticed that the two liquid should be at the same temperature and that re-
suspension was required. An incubation time of at least 8 to ten minutes must be respected before reading 
the plate absorbance at 590 nm. However, the stain is light sensitive, the reading must be done within the 
hours following its preparation. 595 nm is the ideal spectrum for blue, the closest filter was chosen. In this 
assay, the signal increases with time, it is thus absolutely necessary to always measure the zero reference 
with each measurement made. Indeed, their difference is actually the signal to analyze and from which 
the peptide concentration can be obtained.  
 In order to determine the concentration of an unknown peptide solution from the absorbance 
measured by spectrophotometry at 590nm, a calibration curve needs to be used. 
 The calibration curve of LL37 with Coomassie Blue absorbance was performed by following the 
provider’s protocol with solutions which concentrations were known. LL37 solutions were by serial 
dilution from a 25.4 µg/mL solution down to a 1.1 µg/mL concentration. The assay was performed two 
times with 3 replicates for each experiment. 
The provider’s protocol advises to approach the calibration using 4th order polynomial form which gives: 
 
Figure 27: Quadratic calibration curve at 590 nm for LL37 quantification by Bradford assay (Mean ± st dev; n= 3) 
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In spite of a high correlation factor, the function obtained from that regression is not monotonous on the 
[20µg/mL ; 25µg/mL] interval. Within that range the solver can converge to two concentrations for a same 
absorbance. The goal being to use the curve to determine the concentration of unknown solutions 
anywhere within the range [1/mL ; 25µg/mL], another regression must be used. The one that fits the best 
(higher correlation factor) is a under a power form: 
 
Figure 28: Calibration curve at 590 nm for LL37 quantification by Bradford assay(Mean ± st dev; n= 3) 
That calibration curve is used to quantify LL37 by performing Bradford assays in this study.  
2) Results and Discussion: 
 The total mass of LL37 trapped in each batch produced is necessary to determine the 
encapsulation efficiency. For each process, a 15 mg sample of capsules produced are dispersed in 1 mL 
DCM with a vortex stirrer.  They dissolve overnight in containers kept air tight with parafilm to avoid the 
evaporation of the solvent.  
 A liquid liquid extraction is then performed using a total of 1mL PBS solution. To have a good 
extraction by improving the transport of the peptide to the aqueous phase, the extraction is performed 
in two steps. 0.5 mL is first added to the organic phase. The mixture is vortexed and centrifuged. The 
aqueous supernatant is recovered and another 0.5mL of PBS is added to the organic mixture. After 
vortexing and centrifuging, the peptide solution is taken out. The overall aqueous phase recovered is 
mixed. However, it is never possible to recover the entire 1mL solution involved in the extraction with 
that method. 
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 After extraction was done for the capsules obtained from each process presented in part II, the 
solutions obtained for each of them were analyzed performing a Bradford assay. 
 The concentrations in µg/mL were obtained from the calibration curve using Microsoft Excel’s 
solver. The extracting volume being 1mL total, the result was actually giving the mass trapped in 15mg of 
microspheres. Using the total mass of each batch obtained at the end of the synthesis, the total mass 
really trapped in each batch was extrapolated. The encapsulation efficiency is the ratio between this mass 
really encapsulated in the batch and the mass used for encapsulation (always 153µg for all the synthesis 
carried out in this study). 
 For each sample, three replicates were analyzed. The encapsulation efficiency was calculated for 
each replicate: 
 
Table 11: Encapsulation Efficiencies for each process studied 
 While an improvement in the encapsulation efficiency was expected using oil as the continuous 
phase, we notice that there is actually no distinct difference between the two main synthesis methods. 
However, we can notice that the volume of the peptide solution used has a significant impact on that 
feature. Indeed, by using a bigger volume, we increase the ratio inner phase with respect to the polymer 
phase volume leading to a larger contact surface between them after emulsion which promotes their 
transport [40]. Moreover, the spheres volume shrinkage during the solvent evaporation expels a part of 
the inner solution while the polymer hardens [29]. If the volume is more important, more of it will get out 
of the capsules during that step. As a result, less peptide is trapped in the polymer matrix. 
 The comparison between those different encapsulation efficiencies shows that the nature of the 
continuous is not a determining factor to that feature contrary to the peptide solution volume: the smaller 
it is compared to the polymer phase, the more volume of active phase will be trapped.  
ee % AVG ST DEV
W/O/W 9.916111141 8.35146701 10.7544177 9.67399863 1.21963392
W/O/O Vi=0.2mL 8.5907745 11.3220006 10.7270039 10.2132596 1.43626209
W/O/O Vi=0.4mL 7.621036393 9.16701333 8.1814759 8.32317521 0.78266864
ee %
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PART IV – Results & Discussion LL37 Release 
  
 Dispersed in aqueous solution, the capsules slowly releases the peptides. The cumulative mass 
released in the media is measured by extracting and submitting the supernatant to a Bradford Assay. 
I – Release Profiles using Bradford Assays method 
1) Protocol 
 Different diffusion conditions are tested by dispersing 40 mg capsules samples in 1mL solutions. 
The suspension is agitated with a plate shaker all along the experiment. The samples are centrifuged and 
the supernatant is taken and replaced by fresh solution on a regular basis. For each time point, the 
supernatant is analyzed with a Bradford assay giving the concentration and a cumulative release curve 
can be drawn. When the concentration released between two samples gets below 1µg/mL, the lowest 
detection limit of the assay is reached and or the release is not taken into account for the cumulative mass 
release calculation, or the experiment is stopped. 
2) Impact of the process and formulation on the release profile at room 
temperature in PBS 
 A diffusion study at room temperature was carried out in PBS for samples of capsules made from 
each process tested in this study. Diffusion took place over 73 hours before the lower detection limit of 
the assay giving the concentrations was reached. 
  
Figure 29: Release profile of LL37 from 40mg of capsules depending on the synthesis process (Mean ± st dev; n= 3)  
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 The capsules produced through the water based process present a more important burst effect 
than the two others. Indeed, in the case of the oil based process, the solvent phase is made up of 50% v/v 
DCM and AN. DCM is soluble with paraffin while AN is not: it is quickly extracted from the polymer phase 
which results in the formation of a non-porous hard layer at the microspheres surfaces [34; 23]. The 
presence of this skin prevents from a quick burst effect. 
 Nonetheless, the delivery system obtained by using an inner volume of 0.4mL has the highest 
release over time. The porous structure obtained from a bigger inner volume enables a much faster 
release than when the volume is halved: more active substance is delivered before the polymer erosion 
starts [40]. 
 To conclude, the oil based synthesis process can be used to reduce the capsules burst effect. A 
faster release can be achieved by increasing the volume of the peptide solution with respect to the 
polymer phase: the product obtained is more porous. 
3) Temperature impact on the release profile: 
 The ultimate aim is to use the capsules against bacteria. For that reason, it is interesting to study 
their diffusion in complete physiological conditions versus ambient release. 
40 mg samples of capsules produced by the oil based process with a 0.2mL inner volume were suspended 
in 1 mL of PBS. When diluted with 1 liter of water, the Phosphate Buffer Saline powder used gives a 
solution which salt concentrations are the same as in the physiological conditions: [NaCl]= 0.138 mol/L; 
[KCl]= 0.0027mol/L at pH 7.4. One of the sample is incubated at 37°C while the other stays at room 
temperature (20°C). The same protocol as previously presented is followed to plot the cumulative release 
curves. 
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Figure 30: Temperature impact on release profile of 40mg w/o/o capsules (Mean ± st dev; n= 3) 
The burst effect and the amount released is significantly higher at 37°C than at 20°C in agreement with 
the studies carried out by Dunne et Al. on plain PLGA microspheres. Indeed, that observation can be 
explained by the impact of temperature on PLGA: 
-  According to the material provider Sigma, the glass transition temperature of PLGA is between 
45°C and 50°C, increasing the temperature up to 37°C brings the material closer to its amorphous 
domain,  
- At 37°C the temperature, the rate of PLGA hydrolysis is higher than at 20°C which can trigger an 
earlier matrix erosion causing the release of LL37. 
A warmer environment can also impact the peptide solubility: LL37 crystals trapped in the matrix dissolve 
faster in the media at 37°C leading to a higher concentration gradient from the spheres to the supernatant. 
 Temperature has a strong impact on peptide release. Thus, it is very important to define the 
conditions of use for the capsules and carry out studies on them to make the right adjustment depending 
on the release profile and amount to be delivered desired.  
4) pH impact on LL37 release profile: 
Three 40 mg capsules samples produced based on the w/o/w process are placed in media at different pH: 
acidic at pH 4.2, neutral at pH 7.4 and alkaline at pH 10.2. 
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Figure 31: Impact of pH on LL37 release profile from w/o/w capsules (Mean ± st dev; n= 3) 
PLGA is an ester which hydrolysis occurs in acidic conditions (pH>7) according to the reaction presented 
in Figure 5. The H+ ions are consumed by the reaction which is a total one. 
Nonetheless, at basic pH (>7), PLGA is in presence of H+ ions which catalyze its hydrolysis according to: 
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Figure 32: Saponification of PLGA 
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 This reaction is total while hydrolysis is in equilibrium with the esterification. For that reason, 
there is no significant difference in the release profiles at pH 7.4 and at pH 4.2 given the standard 
deviation. PLGA degradation is thus much faster at pH 10.2 than at pH 7.4 and 4.2. The release of LL37 is 
faster and more important when the pH increases in alkaline environment [39].  
II – Antimicrobial feature 
 The role of the microspheres is to protect and deliver LL37. The antimicrobial properties of the 
peptide were assessed and characterized to use the information for designing the capsules. Then, it was 
necessary to verify the antimicrobial efficacy of the delivery system and of the peptide within it. E.Coli is 
a very common bacteria and was used for the tests. 
1) Minimum Inhibitory Concentration Assay 
The minimum concentration of LL37 to inhibit bacteria growth is determined by performing a Minimum 
Inhibitory Concenration Assay in a microplate. The media used in the study is sterilized Mueller Hinton 
broth. 
The wells are filled with 100µL of known LL37 samples of various concentrations by serial diluting a 6 
µg/mL solution in Mueller Hinton broth. Bacteria is prepared from a solution made up of 10% v/v Mac 
Farland standard 0.5 (108 cfu/mL) and 90% v/v fresh media. Then 100µL of the 107 cfu/mL media 
containing bacteria is added to the wells. The bacteria in contact with LL37 will be compared to the growth 
controls that do not contain peptide solution. It is important to include several blank controls (sterile medi 
a) in case there is contamination. The plate is incubated at warm temperature (37°C) overnight. The media 
becomes more turbid as bacteria grew in it is, the plate is read by spectroscopy at 600nm one day later: 
the absorbance read will increase with bacteria density. The experiments were all carried out on three 
replicates. 
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Figure 33: E.Coli normalized Optical Density after 1 day incubation at 600nm in function of LL37 concentration in M-H Broth 
(Mean ± st dev; n= 3) 
Thanks to those results, the range LL37 concentrations to use to inhibit E.Coli MacFarland 0.5 standard 
growth. The time point at which the amount of peptide released from the capsules is concentrated 
enough to kill E.Coli can be determined by comparing the MIC assay with the release profile obtained in 
specific conditions. 
2) Zone of Inhibition Assay 
In order to test antimicrobial properties of the capsules in physiological conditions, the diffusion 
experiment is carried out again at 37°C in PBS with two 40mg samples: one from the aqueous process and 
one produced by the oil based one with 0.2 mL of solution trapped. To obtain LL37 concentrations 
released higher than the MIC, the suspensions are shaken in the warm room for 8 hours. The supernatant 
is recovered and used to fill super absorbent paper pellets keeping approximately 100 µL of liquid each. 
At the same time, two control pellets are prepared: 
- Negative control which is only PBS absorbed by a pellet, 
- Positive control consisting in a pellet that absorbed a 3µg/mL LL37 solution.  
A thin E.Coli MacFarland standard biofilm is evenly distributed on M-H agar plate. The prepared pellets 
are laid out on the plate. To have three replicates, three plates are prepared. They are incubated overnight 
at 37°C. 
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The study showed no area where bacteria growth was inhibited around any pellet including the positive 
control. Thus, no conclusion could be drawn from the Zone of Inhibition Study. From several students 
attempts with the procedure, that assay seems hardly representative of LL37 antimicrobial activity when 
it is clear in solution through the MIC assay. Some possible explanations are that LL37 has a strong affinity 
with the pellet material or that LL37 is not mobile enough to diffuse out of the pellet and in agar. This 
assay is not significant in this study, choosing another more adapted bacteria assay is necessary. 
  
58 
  
PART V- Conclusion & Prospects 
I Conclusion 
In this study, microspheres loaded with LL37 were synthesized by two processes: 
- Water in oil in water double emulsion with solvent evaporation, 
- Water in oil in oil double emulsion with solvent extraction (DCM)/evaporation (AN) for which the 
formulation and equipment used was playing an important role into the procedure success.  
After purification and freeze drying, white free flowing powders were obtained. 
 Using microscopy imaging analysis, the products from the last process were measured to be 
bigger than the one obtain from the water based synthesis, which is explained by the viscosity difference 
between paraffin and water. Nevertheless, the capsules all responded to the size specification required 
involved by the project: size between 0.1 and 100 µm.  
Considering the initial mass of LL37 involved in the encapsulation, the amount really trapped into the 
polymer matrix is not significantly different from one process compared to the other. In spite of a 
difference in the continuous phase chemical nature, the encapsulation efficiency is around 10%. 
By doubling the volume of the peptide solution involved in the oil based synthesis only, the porosity of 
the capsules was increased. As a result of this change in inner volume at a constant PLGA mass, the 
encapsulation efficiency dropped to 8% defining the volume encapsulated as a determining parameter to 
the encapsulation efficiency. 
LL37 release profiles from capsules obtained by the two types of processes and with different porosities 
were experimentally determined using Bradford assays to quantify the amount released. The influence of 
different parameters on the peptide diffusion in PBS (physiological salt concentrations) were determined: 
- Capsules obtained from the oil based process show a considerably lesser burst effect than the 
ones made in water. The hard non porous polymer skin at their surface formed by the fast 
extraction of DCM by paraffin in the process, 
- The total mass released for a same formulation and process is much higher when the polymer 
matrix is more porous which is done by using a more voluminous peptide solution while the same 
mass of drug, 
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- At 37°C, more peptide is released; the diffusion plateau is much higher than at 20°C. Increasing 
the temperature contributes to increase the rate of PLGA hydrolysis, the matrix starts eroding 
earlier. 
- The same phenomenon happens in alkaline condition (pH 10.2) where PLGA goes through 
saponification by the hydroxide ions. This total reaction results in the capsules erosion. 
- The release profile is the same in weakly acidic environment (pH 4.2) as in neutral media (pH 7.4) 
since the hydrolysis reaction of PLGA by H+ ions is an equilibrium. 
The process and peptide solution volume involved in the synthesis must be determined according to the 
type of release profile wanted in given known conditions (temperature, pH). 
 After diffusion, the supernatant was tested against E.Coli after determining LL37 MIC against the 
bacteria. A zone of Inhibition assay was carried out to compare the activity of encapsulated and released 
AMP against regular AMP solution. Unfortunately, the no area where the bacteria growth was inhibited 
appeared, including for the positive control. This type of assay is not adapted to LL37 that might have 
problems migrating through the pellets and in agar. Another solution based assay must be performed to 
assess the capsules antimicrobial activity. 
II Future Work 
1) Methods improvements 
Other analytical technics can be used to obtain more accurate characterization results: 
- DLS cannot be applied to particles bigger than 10µm but LASER diffraction sizers provide size 
distributions for microparticles, the technic will give a more accurate and representative result 
than the ones obtained by microscopy analyze, 
- The Bradford Assay used to quantify the proteins has a 1µg/mL detection limit and also requires 
450µL of sample for each measurement (for three replicates), chromatography with detectors 
adapted for protein quantification would be a good alternative for more accuracy, smaller 
concentration measurements and it would involve the use of less synthesized material. 
2) Complementary studies 
 First, the capsules can be further characterized by measuring their specific surface area, which 
defines their porosity. Isothermal BET (Brunauer–Emmett–Teller) adsorption studies will provide it.  
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It would also be interesting to monitor the evolution of the porosity, general structure and drug loading 
of the spheres over time in normal conditions to define their shelf life and the best conservation 
conditions for them. Comparing it with the free peptide conservation conditions will demonstrate interest 
in encapsulating LL37. 
 The synthesis processes carried out in this study involve toxic organic solvents that could be 
denature LL37 and be toxic toward the organism if some of it is left in the capsules. 
It is necessary to make sure that LL37 has not been degraded during the encapsulation. Electrophoresis 
[41] using a method (gel, current, mobile and stationary phases) adapted to peptides (small kDa). If LL37 
is properly encapsulated, further studies on the capsules antimicrobial properties should be carried out 
using a liquid based assay such as live and dead cells assays [42]. However, determining the amount of 
residual organic solvent in the capsules needs to be done first (using chromatography) in order to make 
sure those residues cannot impact the reliability of the assay by contributing to bacteria death too.  
Finally, MTT assays should be performed on the microspheres to determine their toxicity potential 
towards healthy cells. 
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Appendix 1- Microscopy  
1/ Sample of the pictures taken for Batch 4 size analysis  
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2/ Sample of the pictures taken for Batch 5 size analysis  
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3/ Sample of the pictures taken for Batch 2 size analysis  
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4/ Sample of the pictures taken for Batch 3 size analysis  
  
70 
  
5/ Sample of the pictures taken for Batch 6 size analysis  
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6/ Sample of the pictures taken for Batch 7 size analysis  
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7/ Example of full statistical size analysis on Batch 5  
area d (um) frequency area d (um) frequency 
140.009 13.3515915 0.00132944 6828.945 93.2463555 0.01056618 
234.515 17.2798661 0.00163578 6842.946 93.34189547 0.010563837 
2157.891 52.4167164 0.00643596 6986.455 94.31559141 0.010536139 
2660.173 58.1982599 0.00741644 7019.707 94.53977229 0.010528774 
2898.189 60.7461015 0.00783569 7073.961 94.90440919 0.010516006 
3165.956 63.4903172 0.00827125 7273.474 96.2334387 0.010461279 
3276.213 64.5864068 0.00843935 7275.224 96.2450149 0.010460746 
3363.719 65.4432582 0.00856807 7779.257 99.52315128 0.010271741 
3743.494 69.0388629 0.00907847 8369.045 103.2269298 0.009970778 
3783.747 69.4090506 0.00912798 8657.814 104.9927195 0.009796923 
3927.256 70.7130656 0.00929737 8745.32 105.5219752 0.009741225 
4401.537 74.8612781 0.00977892 8801.323 105.8593052 0.009704888 
4450.54 75.2768459 0.00982193 8869.578 106.2689863 0.009659894 
4455.79 75.3212323 0.00982647 8929.082 106.6248578 0.009620054 
4496.043 75.6606882 0.00986076 9055.09 107.3745718 0.009533867 
4506.544 75.7489936 0.00986957 10784.203 117.1788109 0.008171068 
4525.795 75.910613 0.00988557 12173.793 124.4996171 0.006966569 
4567.798 76.2620551 0.00991982 22322.704 168.5886991 0.001196975 
4688.555 77.2635337 0.01001329 47776.363 246.6389156 1.82414E-06 
4713.057 77.465157 0.01003135 50989.572 254.7978403 7.22184E-07 
4765.56 77.8954392 0.01006904 80305.732 319.7630899 8.42307E-11 
4788.312 78.0811641 0.01008494 average diameter (um) ST DEV # of particles 
5047.329 80.1651974 0.01024799 85.46 4.42 60.00 
5094.582 80.5395758 0.01027422       
5140.085 80.8984517 0.01029847       
5185.588 81.2557426 0.01032173       
5402.602 82.9385707 0.01041936       
5610.866 84.5220473 0.01049287       
5630.117 84.6669216 0.0104987       
5633.617 84.6932343 0.01049974       
5696.621 85.1655043 0.01051757       
5728.123 85.40066 0.01052584       
5770.126 85.7131997 0.01053621       
5805.128 85.9727779 0.01054427       
5962.638 87.1313175 0.01057419       
5992.39 87.3484282 0.01057869       
6470.172 90.7638631 0.01060316       
6736.189 92.6109184 0.01058002       
6743.189 92.6590249 0.01057908       
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Appendix 2- Bradford Assay Calibration Curve 
 
 LL37 peptide ABS 1 ABS 2 
concentration (ug/mL) 1 2 3 1 2 3 
25.38461538 0.607 0.647 0.643 0.603 0.645 0.643 
17.69230769 0.566 0.598 0.610 0.567 0.613 0.610 
12.69230769 0.523 0.498 0.516 0.499 0.493 0.507 
8.846153846 0.448 0.438 0.458 0.434 0.442 0.453 
6.346153846 0.414 0.413 0.411 0.401 0.414 0.416 
4.423076923 0.397 0.405 0.405 0.397 0.404 0.405 
3.173076923 0.363 0.356 0.362 0.363 0.355 0.362 
2.211538462 0.341 0.349 0.352 0.341 0.349 0.352 
1.586538462 0.339 0.335 0.336 0.338 0.335 0.336 
1.105769231 0.325 0.329 0.329 0.325 0.329 0.329 
0 0.285 0.282 0.283 0.286 0.283 0.284 
 
 LL37 peptide ABS 1 corrected ABS 2 corrected 
conc (ug/mL) 1 2 3 AVG ST DEV 1 2 3 AVG ST DEV 
25.38461538 0.323 0.364 0.360 0.349 0.022316 0.318 0.361 0.358 0.346 0.023754 
17.69230769 0.283 0.314 0.327 0.308 0.022864 0.283 0.329 0.325 0.312 0.025456 
12.69230769 0.240 0.214 0.233 0.229 0.012949 0.215 0.209 0.222 0.215 0.006903 
8.846153846 0.165 0.155 0.175 0.165 0.010147 0.149 0.158 0.169 0.159 0.009808 
6.346153846 0.131 0.130 0.128 0.130 0.001665 0.117 0.129 0.131 0.126 0.007893 
4.423076923 0.114 0.122 0.122 0.119 0.004606 0.113 0.120 0.121 0.118 0.004051 
3.173076923 0.080 0.072 0.078 0.077 0.003825 0.079 0.071 0.077 0.075 0.00439 
2.211538462 0.058 0.066 0.069 0.064 0.005488 0.057 0.065 0.067 0.063 0.005463 
1.586538462 0.056 0.052 0.053 0.053 0.002106 0.054 0.050 0.052 0.052 0.001905 
1.105769231 0.042 0.046 0.046 0.045 0.002351 0.041 0.044 0.045 0.043 0.002138 
AVG 0 0.283 0.001347 0.284 0.001647 
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Appendix 3- Encapsulation Efficiency 
 
capsules ABS    Solver equation 
BLANC 0.274 0.272 0.270     
W/O/W 0.319 0.314 0.322  2.9066E-11 6.6392E-11 1.2199E-10 
W/O/O 0.2 0.311 0.319 0.317  6.4736E-11 1.4649E-10 1.2634E-10 
W/O/O 0.4 0.312 0.317 0.314  2.2039E-11 2.3476E-10 7.435E-11 
 avg zero 0.272      
        
capsules ABS corrected     
W/O/W 0.047 0.042 0.050     
W/O/O 0.2 0.039 0.047 0.045     
W/O/O 0.4 0.040 0.045 0.042     
        
        
        
capsules CONC in ug/mL in 1mL so mass in ug ST DEV    
BLANK    0.00210703    
W/O/W 1.381 1.163 1.498 0.16984586    
W/O/O 0.2 1.044 1.376 1.303 0.17449558    
W/O/O 0.4 1.095 1.317 1.175 0.11240454    
 
capsules mass studied/mass total produced 
W/O/W 10.98666667 
W/O/O 0.2 12.59333333 
W/O/O 0.4 10.65333333 
 
 
Batch total mass 
(mg) 
ee % ee % AVG ST DEV 
W/O/W 164.8 9.91611114 8.35146701 10.7544177 9.67399863 1.21963392 
W/O/O 
Vi=0.2mL 
188.9 8.5907745 11.3220006 10.7270039 10.2132596 1.43626209 
W/O/O 
Vi=0.4mL 
159.8 7.62103639 9.16701333 8.1814759 8.32317521 0.78266864 
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Appendix 4- Diffusion Study 
1/ In physiological conditions (37C, pH 7.2), W/O/O, Vi=0.2mL: 
 
Hours diffusing ABSORBANCE w/o/o Vi= 0.2mL   Solver Equation 
6 0.369 0.360 0.352   -3.2E-07 7.01E-08 2.53E-09 
25 0.356 0.365 0.367   -4E-07 -6.4E-07 8.3E-07 
44 0.317 0.328 0.326   1.93E-07 3.51E-07 3.67E-07 
67 0.314 0.318 0.312   3.02E-07 1.59E-07 7.79E-07 
91 0.303 0.314 0.306   3.98E-07 3.78E-07 8.91E-07 
115 0.311 0.316 0.321   1.48E-07 6.71E-07 1.93E-07 
         
 ABSORBANCE   
blank 0.282 0.276 0.277 0.272 0.271 0.271   
AVG zero 0.274995        
         
Hours diffusing Corrected absorbance      
6 0.094098 0.085148 0.077069382      
25 0.081322 0.089962 0.091670607      
44 0.041857 0.052877 0.051150782      
67 0.039186 0.043159 0.036814962      
91 0.028322 0.039006 0.030854912      
115 0.035526 0.040938 0.046189499      
         
Hours diffusing 
Conc in ug/mL in 1mL so mass 
 
 
     
6 2.65848 2.766309 2.826891654      
25 0.712591 1.02185 1.219891651      
44 1.066699 0.947463 0.920011088      
67 0.764615 1.036911 0.988539706      
91 0.397001 1.17029 1.215612649      
115 1.031439 1.195713 1.154339163      
         
Hours diffusing 
CUMULATIVE MASS (ug) 
 
 
ST DEV  Hours diffusing 
Mass 
released 
(ug) 
ST DEV 
6 3.757342 3.252722 2.816947851 0.470617  0 0 0 
25 6.801267 6.774099 6.435240054 0.203936  6 2.742499 0.071492 
44 7.968671 8.409709 7.994383046 0.247545  25 3.795232 0.303055 
67 9.030098 9.629876 8.964398445 0.366722  44 4.855063 0.35661 
91 9.694479 10.68429 9.716203665 0.5653  67 5.832521 0.495849 
115 10.61587 11.81488 11.06188836 0.606018  91 6.786287 0.816117 
      115 8.163067 1.199927 
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2/ In ambient conditions (20C, pH 7.2), W/O/O, Vi=0.2mL 
 
Hours 
diffusing ABSORBANCE w/o/o Vi= 0.2mL ABSORBANCE corrected 
6 0.311 0.304 0.313 0.0446533 0.03807473 0.04661776 
24 0.297 0.316 0.290 0.03068541 0.04977026 0.02391249 
48 0.288 0.285 0.286 0.02127298 0.01867704 0.01955499 
73 0.278 0.276 0.278 0.01126569 0.00997679 0.01131901 
96 0.274 0.274 0.279 0.00788733 0.00762386 0.01237077 
120 0.271 0.274 0.266 0.00494636 0.00799117 -0.0001676 
144 0.272 0.287 0.275 0.00584663 0.02058579 0.00851172 
173 0.276 0.285 0.275 0.00963186 0.01894116 0.00907293 
 
 Absorbance 
blank 0.267 0.285 0.266 0.277 0.283 
avg blank 0.223     
 
Hours diffusing Conc in ug/mL in 1mL so mass (ug)  Solver equation 
6 1.28157139 1.01826997 1.36371548  3.579E-11 2.2837E-10 1.1737E-10 
24 0.74584172 1.49875855 0.52042632  2.726E-10 1.2341E-10 4.2755E-11 
48 0.43960215 0.36433516 0.38930337  3.3255E-11 6.6371E-11 6.3226E-11 
73 0.17566672 0.14741674 0.17686786  6.8401E-11 8.238E-11 7.6106E-11 
 
Hours diffusing CUMULATIVE MASS (ug) w/o/o Vi= 0.2mL 20C ST DEV 
6 1.28157139 1.01826997 1.36371548 0.18046601 
24 2.02741311 2.51702853 1.88414181 0.3318623 
48 2.02741311 2.51702853 1.88414181 0.3318623 
73 2.02741311 2.51702853 1.88414181 0.3318623 
 
Hours diffusing Mass released (ug) ST DEV 
0 0 0 
6 1.22118562 0.18046601 
24 2.14286115 0.3318623 
48 2.14286115 0.3318623 
173 2.14286115 0.3318623 
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3/ In ambient conditions (20C, pH 7.2), W/O/O, Vi=0.4mL 
 
Hours diffusing ABSORBANCE w/o/o Vi= 0.2mL ABSORBANCE corrected 
6 0.35152929 0.34862079 0.3720166 0.07598679 0.07307829 0.09647411 
24 0.36903763 0.37161297 0.3853345 0.09349514 0.09607048 0.10979201 
48 0.32494577 0.3414249 0.35148397 0.04940328 0.06588241 0.07594148 
73 0.30754365 0.30342055 0.31923771 0.03200116 0.02787805 0.04369521 
96 0.3093764 0.30028799 0.32716695 0.0338339 0.0247455 0.05162445 
120 0.29816815 0.27871156 0.30076943 0.02262566 0.00316907 0.02522694 
144 0.28835308 0.29205302 0.2999119 0.01281058 0.01651053 0.02436941 
173 0.28544576 0.29131009 0.30484912 0.00990327 0.0157676 0.02930662 
 
 Absorbance 
blank 0.26694597 0.28489302 0.26641038 0.27652462 0.28293848 
avg blank 0.22298667     
 
Hours diffusing Conc IN ug/mL in 1mL so mass (ug)  Solver equation 
6 2.76000248 2.60886152 3.89501614  1.8927E-10 1.1766E-10 7.6397E-11 
24 3.72265731 3.87152307 4.69405502  8.0605E-11 2.3687E-10 3.5886E-10 
48 1.48283781 2.24640794 2.75762766  1.0396E-10 4.4927E-10 1.8852E-10 
73 0.79242457 0.64940777 1.24208158  6.273E-11 5.1683E-11 8.1515E-11 
 
Hours diffusing CUMULATIVE MASS (ug) w/o/o Vi= 0.2mL 20C ST DEV 
6 2.76000248 2.60886152 3.89501614 0.70300466 0.18046601 
24 6.48265979 6.48038458 8.58907116 1.2167945 0.3318623 
48 7.9654976 8.72679253 11.3466988 1.77369673 0.3318623 
73 7.9654976 8.72679253 11.3466988 1.77369673 0.3318623 
 
Hours diffusing Mass released (ug) ST DEV 
0 0 0 
6 3.08796005 0.70300466 
24 7.18403851 1.2167945 
48 9.34632965 1.77369673 
73 9.34632965 1.77369673 
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4/ In ambient conditions (20C, pH 7.2), W/O/O, Vi=0.2mL  
 
Hours diffusing ABSORBANCE w/o/o Vi= 0.2mL ABSORBANCE corrected 
6 0.311 0.304 0.313 0.0446533 0.03807473 0.04661776 
24 0.297 0.316 0.290 0.03068541 0.04977026 0.02391249 
48 0.288 0.285 0.286 0.02127298 0.01867704 0.01955499 
73 0.278 0.276 0.278 0.01126569 0.00997679 0.01131901 
96 0.274 0.274 0.279 0.00788733 0.00762386 0.01237077 
120 0.271 0.274 0.266 0.00494636 0.00799117 -0.0001676 
144 0.272 0.287 0.275 0.00584663 0.02058579 0.00851172 
173 0.276 0.285 0.275 0.00963186 0.01894116 0.00907293 
  
 Absorbance 
blank 0.26694597 0.28489302 0.266410381 0.27652462 0.28293848 
avg blank 0.22298667     
 
Hours diffusing Conc IN ug/mL in 1mL so mass (ug)  Solver equation 
6 1.28157139 1.01826997 1.36371548  3.579E-11 2.2837E-10 1.1737E-10 
24 0.74584172 1.49875855 0.52042632  2.726E-10 1.2341E-10 4.2755E-11 
48 0.43960215 0.36433516 0.38930337  3.3255E-11 6.6371E-11 6.3226E-11 
73 0.17566672 0.14741674 0.17686786  6.8401E-11 8.238E-11 7.6106E-11 
 
Hours 
diffusing 
CUMULATIVE MASS (ug) w/o/o Vi= 
0.2mL 20C ST DEV 
6 1.28157139 1.01826997 1.36371548 0.18046601 
24 2.02741311 2.51702853 1.88414181 0.3318623 
48 2.02741311 2.51702853 1.88414181 0.3318623 
73 2.02741311 2.51702853 1.88414181 0.3318623 
 
Hours diffusing Mass released (ug) ST DEV 
0 0 0 
6 3.71474468 0.79494983 
24 4.67884821 0.73920655 
48 4.67884821 0.73920655 
73 4.67884821 0.73920655 
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 5/ At pH 4.2 and 20C, W/O/W, Vi=0.2mL 
 
Hours 
diffusing 
ABSORBANCE w/o/o Vi= 
0.2mL 
ABSORBANCE corrected 
6 0.355 0.402 0.367 0.047 0.094 0.060 
24 0.344 0.335 0.338 0.036 0.027 0.030 
48 0.313 0.304 0.319 0.005 -0.004 0.012 
72 0.334 0.328 0.323 0.026 0.020 0.015 
100 0.349 0.350 0.358 0.041 0.042 0.050 
120 0.311 0.322 0.317 0.003 0.014 0.009 
 
 Absorbance 
blank 0.311354 0.305626 0.307986 0.304909 0.309589 
avg 
blank 0.307893 
    
 
Hours diffusing 
Conc IN ug/mL in 1mL so mass 
(ug) 
 Solver equation 
6 1.394796 3.74181 1.940153  -1.6E-10 8.76E-11 2.61E-10 
24 0.92837 0.619397 0.737956  3.58E-11 1.54E-10 2.53E-10 
48 0.062107 0 0.182743  4.69E-11 0.003598 2.05E-11 
73 0.593228 0.405212 0.273292  4.51E-11 1.66E-10 6.9E-11 
96 1.132783 1.185666 1.495275  4.53E-11 8.07E-11 1.19E-10 
120 0.022329 0.246426 0.130836  3.71E-12 8.07E-11 2.06E-11 
 
Hours diffusing CUMULATIVE MASS (ug)  ST DEV 
6 1.394796 3.74181 1.940153 0.180466 
24 2.323166 4.361207 2.678109 0.331862 
48 2.323166 4.361207 2.678109 0.331862 
73 2.323166 4.361207 2.678109 0.331862 
96 3.455949 5.546873 4.173385 0.331862 
120 3.455949 5.546873 4.173385 0.331862 
 
Hours diffusing Mass released (ug) ST DEV 
0 0 0 
6 2.358919 1.375109 
24 3.120827 1.370313 
48 3.120827 1.370313 
72 3.120827 1.370313 
100 4.392069 1.363922 
120 4.392069 1.363922 
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6/ At pH 10.2 and 20C, W/O/W, Vi=0.2mL 
 
Hours diffusing ABSORBANCE w/o/o Vi= 0.2mL ABSORBANCE corrected 
6 0.412 0.381 0.383 0.103 0.071 0.074 
24 0.419 0.412 0.396 0.109 0.102 0.087 
48 0.329 0.324 0.320 0.020 0.015 0.011 
72 0.364 0.359 0.355 0.055 0.049 0.046 
100 0.368 0.360 0.352 0.058 0.051 0.043 
120 0.363 0.346 0.346 0.054 0.037 0.036 
 
 Absorbance 
blank 0.310 0.310 0.307 0.310 0.310 
avg 
blank 0.308 
    
 
Hours diffusing Conc in ug/mL in 1mL so mass (ug)  Solver equation 
6 4.266286 2.512634 2.645224  3.39E-10 5.42E-10 1.37E-10 
24 4.658871 4.234065 3.332163  4.74E-10 2.93E-10 1.45E-10 
48 0.396674 0.2605 0.168748  8.89E-11 3.08E-11 3.34E-11 
73 1.726891 1.474403 1.32077  1.89E-11 9.45E-11 2.73E-10 
96 1.877743 1.546995 1.21193  4.92E-11 1.96E-10 9.03E-11 
120 1.674466 0.97294 0.956764  2.65E-10 9.52E-11 8.22E-11 
 
Hours diffusing CUMULATIVE MASS (ug) ST DEV 
6 4.266286 2.512634 2.645224 0.180466 
24 8.925157 6.746699 5.977387 0.331862 
48 8.925157 6.746699 5.977387 0.331862 
73 10.65205 8.221102 7.298157 0.331862 
96 12.92647 10.0286 8.678836 0.331862 
120 12.92647 10.0286 8.678836 0.331862 
 
Hours diffusing Mass (ug) ST DEV 
0 0 0 
6 3.141381 0.976449 
24 7.216415 1.52899 
48 7.216415 1.52899 
72 8.72377 1.732528 
100 10.54463 2.170325 
120 10.54463 2.170325 
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Appendix 5- Minimum Inhibitory Concentration 
Assay 
 
Conc (ug/mL) Conc (uM) Absorbance at 600 nm ST DEV AVG abs Normalized 
6.000 1.335313 0.064 0.068 0.066 0.002007 0.065 0.101601 
3 0.667656 0.067 0.066 0.067 0.000471 0.067 0.1036 
1.5 0.333828 0.088 0.082 0.088 0.003716 0.086 0.133529 
0.75 0.166914 0.084 0.084 0.127 0.024833 0.099 0.152994 
0.375 0.083457 0.369 0.394 0.438 0.035161 0.401 0.622025 
0.1875 0.041729 0.581 0.621 0.620 0.022926 0.609 0.945441 
0.09375 0.020864 0.645 0.635 0.648 0.006632 0.644 1 
 
 Absorbance at 600 nm 
Growth control 0.639 0.653 0.654 0.599 0.548 0.574 
 
 Absorbance at 600 nm 
Sterility control 0.064 0.064 
 
